Costs of type 2 diabetes mellitus from payers’ perspective: a study from real-world evidence of district hospital in Vietnam

Objective. Estimate yearly treatment cost of type 2 diabetes mellitus (T2DM) from payers' perspective and its influencing factors. Method. A cross-sectional descriptive study has been conducted based on real-world evidence from Thu Duc district hospital from January 2017 to April 2018. Cost of T2DM was estimated based on payers' perspective and included direct medical, direct non-medical and indirect costs. Result: Analyzing the sample of 206 patients with men: women rate of 1: 2.81 and mean age of 61.76±9.74, it has been shown that the average costs of T2DM per patient was accounted for US $ 1,038.3 (95% CI 951.4-1,125.2) with high proportion for direct costs (93.7%) and drugs cost (68.4% of direct medical costs and 60.6% of total costs). Costs per patient with complication was accounted for US $ 1,677.2 (95% CI 1,541.3-1,813.1), which is higher than those without complications (US $ 306.3 (95% CI 295.7-316.9)). Patients with comorbidities incurred higher average cost than those without them (p<0.05). Patients with previous inpatient hospitalization for T2DM or longer number of years for treating T2DM incurred higher cost (p<0.05). Patients with more risk factors or high HbA1c level also incurred higher costs (p<0.05). Conclusion: The average cost of T2DM was reported an estimate of US $ 1,038.3; in which average cost for patients with complication was 5 times higher than those without complication. HbA1c level, comorbidities and complication were the first 3 factors influencing average cost of T2DM.

Costs, Type 2 diabetes mellitus, Payer's perspective, Vietnam